



Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 2	Phase 2 Reg / Phase 3	Regulatory status
Magrolimab + Azacitidine	CD47 antibody	MDS				FortySeven <sup>1</sup>	Orphan Drug Designation, Fast Track Designation, Breakthrough Therapy Designation
AFM13	CD30/CD16A bispecific engager	PTCL				AFFIMED	Orphan Drug Designation
Pelabresib + Ruxolitinib	BET small molecule	MPN				Constellation <sup>2</sup> PHARMACEUTICALS	Orphan Drug Designation, Fast Track Designation
Duvelisib	PI3Kδ/γ small molecule	PTCL				Verastem <sup>3</sup> Oncology	Orphan Drug Designation, Fast Track Designation
Magrolimab + Rituximab	CD47 antibody	DLBCL				FortySeven <sup>1</sup>	
Cusatuzumab + Azacitidine	CD70 antibody	AML				argenx	Orphan Drug Designation
KO-539	Menin small molecule	AML: NPM1 mutant & KMT2A rearranged				KURA <sup>4</sup> ONCOLOGY	Orphan Drug Designation
STRO-001	CD74 antibody drug conjugate	NHL/MM				SUTRO BIOPHARMA	Orphan Drug Designation (MM)
Mavorixafor + Ibrutinib	CXCR4 small molecule	CXCR4 & MYD88 double mutant Waldenström's				X4 PHARMACEUTICALS	Orphan Drug Designation
RVU120	CDK8/19 small molecule	AML/MDS				RYU THERAPEUTICS	Orphan Drug Designation
PVX-410 + ACY-241 +/- Len	XBP1/CD138/CS1 vaccine	Smoldering myeloma				OncoPep	Orphan Drug Designation
NEXI-001 NEXI-002	T cell therapy	AML MM				NexImmune	Orphan Drug Designation
BTX-A51	CK1-α/CDK7/CDK9 small molecule	AML/MDS				BioTheryX	
IO-202	LILRB4 antibody	AML/CMML				IMMUNE-ONC therapeutics	Orphan Drug Designation
CB-010	CD19/PD1 KO allogeneic CAR	NHL				CARIBOU BIOSCIENCES	
KT-413 KT-333	IRAKIMiD degrader STAT3 degrader	MYD88 mutant DLBCL PTCL/CTCL/LGL-L				KYMER A	
IMT-009	CD161 antibody	NHL				Immunitas THERAPEUTICS	
TBD	<i>in vivo</i> CAR	TBD				ABINTUS	
TBD	CAR macrophage	TBD				carisma THERAPEUTICS	

1: Acquired by Gilead ♦ 2: Acquired by Morphosys ♦ 3: Duvelisib acquired by Secura Bio, added to NCCN guidelines (PTCL) ♦ 4: Licensed from University of Michigan